- Home
- TMO
as 07-09-2025 10:36am EST
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
| Founded: | 1956 | Country: | United States |
| Employees: | 125000 | City: | WALTHAM |
| Market Cap: | 159.1B | IPO Year: | N/A |
| Target Price: | $594.59 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 17.06 | EPS Growth: | 9.37 |
| 52 Week Low/High: | $385.46 - $627.88 | Next Earning Date: | 07-23-2025 |
| Revenue: | $42,898,000,000 | Revenue Growth: | 0.95% |
| Revenue Growth (this year): | 2.94% | Revenue Growth (next year): | 6.08% |
Latest Thermo Fisher Scientific Inc News
TMO Breaking Stock News: Dive into TMO Ticker-Specific Updates for Smart Investing
MT Newswires
3 hours ago
UBS Downgrades Thermo Fisher Scientific to Neutral From Buy
Zacks
4 hours ago
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
MT Newswires
a day ago
Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $480 From $500, Maintains Outperform Rating
Morningstar Research
a day ago
Analyst Report: Thermo Fisher Scientific Inc.
Insider Monkey
a day ago
Thermo Fisher’s Oncomine Dx Express Test Receives FDA Approval
Insider Monkey
2 days ago
Thermo Fisher Scientific (TMO) Traded Down due to Concerns Over Spending Cuts
StockStory
2 days ago
1 Healthcare Stock for Long-Term Investors and 2 to Question
Insider Monkey
3 days ago
FDA Approved Thermo Fisher Scientific’s (TMO) Oncomine Dx Express Test
Compare TMO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TMO Thermo Fisher Scientific Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.